# Celltrion signs $127.5M biosimilar supply contracts in multiple countries

Celltrion has signed contracts worth about 160.1 billion won ($127.5 million) to supply biosimilar products including Remsima, CT-P16, and Herzuma in multiple countries.

- Type: Contract
- Announced: 2022-05-25
- Value: $127.5M
- Status: announced
- Products: Remsima (infliximab), CT-P16 (bevacizumab), Herzuma (trastuzumab)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Celltrion](https://endata.com/companies/15585.md)

## Sources

- [pulse.mk.co.kr](https://pulse.mk.co.kr/news/english/10330560), 2022-05-25: "Celltrion has signed fresh contracts worth about 160.1 billion won ($127.5 million) in multiple countries to deliver its key biosimilar products."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.